news

  • 2 December 2015
    Axonics Announces Presentation of Study on Costs Savings Associated with Rechargeable Neuromodulation Devices for the Treatment of Overactive Bladder

    Axonics Modulation Technologies, Inc. today announced that on Saturday, December 12, 2015, Karen L. Noblett, M.D., University of California, Riverside, will present results from an abstract titled “Cost Profile of Rechargeable vs. Non-rechargeable Neuromodulation Devices in the Treatment of Overactive Bladder Syndrome” at the North American Neuromodulation Society (NANS) Conference, December 10-13, 2015 in Las Vegas.

    The study uses a cost-consequence model to estimate long-term treatment cost differences between rechargeable and non-rechargeable Sacral Neuromodulation (SNM) devices.  The model considered from a U.S. payer perspective the initial procedure costs, adverse event costs and replacement procedure costs based on the latest published clinical data. The analysis concludes that, at current reimbursement rates, rechargeable device technology for SNM results in significantly lower costs per patient for treatment of Overactive Bladder. Today, the only SNM device available is non-rechargeable, and this study suggests that introduction of a rechargeable system, such as the miniaturized Axonics SNM System, may deliver significant cost savings to U.S. healthcare payers.

    Physicians and researchers collaborating on the study included Karen L. Noblett, MD, University of California, Riverside; Roger R. Dmochowski, MD, Vanderbilt University; Sandip P. Vasavada, MD, Cleveland Clinic, and Abigail M. Garner, MS; Shan Liu, PhD; Jan B. Pietzsch, PhD of Wing Tech, Inc., Menlo Park, CA.